Krystal Biotech (NASDAQ:KRYS) Releases Earnings Results, Beats Expectations By $0.03 EPS

Krystal Biotech (NASDAQ:KRYS) released its quarterly earnings results on Monday. The company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.03, Briefing.com reports. The business had revenue of $70.28 million for the quarter, compared to the consensus estimate of $65.27 million. Krystal Biotech’s revenue was up 70283900.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.25) earnings per share.

Krystal Biotech Trading Down 0.4 %

KRYS stock traded down $0.76 during trading on Wednesday, hitting $177.85. The company had a trading volume of 108,240 shares, compared to its average volume of 380,142. The stock has a market cap of $5.08 billion, a PE ratio of 95.51 and a beta of 0.84. Krystal Biotech has a one year low of $93.95 and a one year high of $219.34. The business has a 50-day moving average of $185.89 and a 200-day moving average of $164.54.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the completion of the transaction, the insider now owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Julian S. Gangolli sold 20,000 shares of the stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $164.13, for a total transaction of $3,282,600.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total value of $4,394,000.00. Following the transaction, the insider now directly owns 1,525,882 shares in the company, valued at $268,189,020.32. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Analyst Ratings Changes

KRYS has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price objective on shares of Krystal Biotech in a research report on Monday. Chardan Capital lifted their price objective on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday. Citigroup reaffirmed a “neutral” rating and issued a $204.00 target price (up previously from $195.00) on shares of Krystal Biotech in a report on Tuesday. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $204.00 target price (up previously from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $185.63.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).